A pentapeptide agonist at the ghrelin receptor, GHS-R1a, on pituitary somatotrophs and the hypothalamus. Notable for selectivity: unlike earlier GHRPs, it releases GH with minimal effect on ACTH, cortisol, or prolactin at comparable doses. Acts through a pathway separate from GHRH, which is why the two classes are often studied together.
Preclinical characterisation is reasonably good. Early human work was conducted by the original developer but development was discontinued. No controlled trials establish clinical benefit for any indication.
Not FDA-approved. No approved product anywhere. Was subject to FDA 503A bulk substance review. Prohibited in sport (WADA S2).
Human safety data are limited to small early-phase studies. Ghrelin-receptor agonism affects appetite and glucose handling. Long-term consequences are unknown.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.